News and Announcements
Proteomics Granted US Patent for Diagnostic Test
- Published October 28, 2015 6:30PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
27th October 2015, ASX Announcement
- Grant of US patent is a critical milestone in the development of the Diagnostic Test for Diabetic Kidney Disease in the world’s largest health care market
- Patent provides protection as both a predictive and diagnostic test in the USA
- Ability to accurately detect early onset of Diabetic Kidney Disease via a simple blood test has the potential to save health care systems globally $100s of millions annually
Life sciences company Proteomics International Laboratories Ltd (ASX:PIQ) (the Company, PILL) is pleased to announce it has been granted a US patent for its PromarkerD Diagnostic Test for the early diagnosis of diabetic kidney disease (DKD).
The patent provides protection for the use of PromarkerD as both a predictive (prognostic) and diagnostic test in the USA, and is valid until 20 September 2031. The patent entitled, “Method of assessing diabetic nephropathy using CD5 antigen-like “(patent number: US 9,146,243 B2).
To read the full announcement, please click here.